Slide 1: We at Sera aim to change pregnancy care
Exhibit 99.1 { WE AT SERA AIM TO CHANGE PREGNANCY CARE } In order to transform the experience into one with fewer uncertainties ©2025 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United S
Slide 2: Safe Harbor Statement
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue
Slide 3: Preterm Birth is a Persistent Clinical & Economic Challenge
DID YOU KNOW? Preterm Birth is a Persistent Clinical & Economic Challenge Preterm birth contributes to 1 in 10 The US rate rose from % BABIES 34.2 % % ARE BORN 9.6 to 10.4 1 2 3 TOO SOON of newborn deaths 2013-2023 4,5 Preterm birth causes numerous medical issues requiring more hospital time and ped
Slide 4: Preterm birth is a prevalent complication and a leading cause of neonatal morbidity and mortality
Preterm birth is a prevalent complication and a leading cause of neonatal morbidity and mortality Preterm Birth Prevalence Mortality 1 2 Any birth before 37 weeks of gestation 10.4% in 2023 34.2% of newborn deaths are attributed to preterm birth 4 3 Median hospital length of stay by gestational week
Slide 5: Health impacts of preterm birth drive increased expenditures
The health impacts of preterm birth drive increased expenditures, with significant cost of care reductions as gestational age at birth increases 3 Expenditure distributions stratified by gestational age In the U.S., the cost to manage the complications of prematurity in 2016 was on average, $64,815
Slide 6: Identifying patients at higher risk of preterm birth is a clinical challenge
Importantly, an 50% effective treatment to reduce PTB OF PREGNANT “ ACOG defined characteristics of should be available, WOMEN who deliver an effective screening program and the screening prematurely have no 1 program should be known risk factors feasible, cost- effective, and accessible to all IDEN
Slide 7: Sera discovered a biomarker risk predictor that fills a critical diagnostic gap
Given the limitations of current screening practices for pregnancy complications, scientists at Sera discovered a biomarker risk predictor that fills a critical diagnostic gap Answers provided by PROTEOMICS Proteomics provide insights into the biology of each pregnancy and go beyond genetic inherita
Slide 8: Biologically important proteins are powerful predictors of spontaneous preterm birth
Biologically important proteins are powerful predictors of spontaneous preterm birth, ® PreTRM looks at each and their interaction Precise mass spectrometry measurements of proteins on blood drawn at 18-20 weeks are used algorithmically to generate a single probability score for preterm birth that i
Slide 9: PreTRM test is validated for prediction during weeks 18-20 of pregnancy
SERA’S PRETRM® TEST IS VALIDATED FOR PREDICTION DURING WEEKS 18-20 OF PREGNANCY ® o The PreTRM Test is highly predictive of spontaneous preterm birth with a single blood 2 draw between 18 and 20 6/7 weeks of gestation PAPR o Three Independent Studies (discovery, verification, Validation validation)
Slide 10: PreTRM was designed to screen women without obvious risk factors
® PreTRM was designed to screen women without obvious risk factors for preterm birth After a physician places the order { OUR TESTING PROCESS SEAMLESSLY INTEGRATES INTO WOMEN’S HEALTH CLINICS } Blood sample kits are Sample collection can be Results delivered in an provided for testing performed by s
Slide 11: The PreTRM Test
® THE PRETRM TEST The first of its kind to detect premature birth ® The PreTRM Test predicts a patient’s individual risk of spontaneous preterm delivery in asymptomatic singleton pregnancies through a single blood collection performed during weeks 18 through 20 of gestational age. ©2025 Sera Prognos
Slide 12: Test Report
TEST REPORT Communicates a patient’s risk of spontaneous preterm birth & helps Final physicians engage with patients Pregnancies identified as higher risk by the PreTRM Test are at increased risk for*: Longer neonatal Spontaneous hospital length preterm birth of stay Severe adverse neonatal outcomes
Slide 13: PreTRM identifies those who may benefit most from targeted interventions
AS A RISK STRATIFICATION BIOMARKER TEST ® PreTRM identifies those who may benefit most from targeted preterm birth interventions Follow Patient with Regularly ® Does Patient Meet PreTRM Testing Criteria*? NO *PreTRM TESTING Scheduled Office Visits CRITERIA ® o Single Fetus Provider Orders PreTRM Blo
Slide 14: PreTRM value has been demonstrated in multiple studies
PreTRM value has been demonstrated in multiple studies Validation Clinical Utility Historical Controlled Randomized Biomarker Validation Trial Controlled Trial Studies AVERT PRETERM TRIAL PRIME TRIAL (2025) PAPR Study (2016) (2024) 5,018 patients 5,501 patients 1,460 patients screened 19 sites 11 si
Slide 15: The AVERT PRETERM Trial study design
Neonatal outcomes after proteomic biomarker guided intervention: The AVERT PRETERM TRIAL S T U D Y D E S I G N Screened with the Historical ® Controls PreTRM Test High Risk Low Risk The AVERT PRETERM Trial studied the health Treated with Declined Historical Normal Care Interventions Treatment N=939
Slide 16: AVERT study results: reduced neonatal hospital stay
AVERT STUDY RESULTS PreTRM helped reduce the length of time a baby spent in the hospital on average by one week Neonatal length of hospital stay (days) for babies with the longest hospital stays Reduction in neonatal hospital length of stay Length of stay (days) 7 Days Reference: Hoffman MK, Kitto C
Slide 17: AVERT study results: positive impact on neonatal health
AVERT STUDY RESULTS Positive Impact on Neonatal Health Severe morbidity and mortality rates were *Severe neonatal morbidity and significantly reduced mortality are defined as Neonatal Composite Morbidity & Mortality Index (NMI) ≥3 NMI scores were significantly 0-4 score given (4 = infant mortality)
Slide 18: AVERT study results
AVERT Study Results The AVERT study achieved statistically significant reductions in neonatal length of stay (NNLOS)* and neonatal morbidity/mortality (NMI), its two co-primary outcomes, in the mITT and ITT population. • In the full mITT and ITT population neonates were discharged earlier from the h
Slide 19: The PreTRM Test is the first step to reduce the harms
Imaginary Imaginary ® The PreTRM Test Mother A Mother B without PreTRM with PreTRM is the first step to reduce the harms Risk of Singleton o Perceived as low-risk o Higher-risk result from Spontaneous o Normal cervical length the PreTRM Test of preterm birth Preterm Birth o No history of preterm bir
Slide 20: PRIME study
PRIME STUDY In 2024, Sera completed a pivotal multicenter national trial: PRIME Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) A pioneering clinical trial assessing the efficacy of the Achievement of one or more PreTRM Test and preventive int
Slide 21: PRIME trial study design
PRIME TRIAL Study design of the Prematurity Risk Assessment Combined with Clinical Interventions for Improving Neonatal Outcomes - ITT constitutes the full analysis Enrolled and Randomized set with multiple imputation of 1:1 N=5018 (ITT) missing outcomes. (n=5,018) The Randomized Controlled Trial In
Slide 22: PRIME study participants' characteristics
PRIME Study Participants’ Characteristics (ITT) • No significant differences between arms for major clinical and demographic characteristics • Diverse population • 27-28% of subjects on pre-enrollment low-dose aspirin (independent of the bundled intervention) Reference: Iriye, B.K. et al. Neonatal I
Slide 23: Co-primary outcomes
Co-Primary Outcomes 1. Neonatal Composite Morbidity and Mortality Index (adapted from Hassan, 2011) Index Morbidity event defined as: Morbidity Criteria NICU Criteria Score • Respiratory distress syndrome • Bronchopulmonary dysplasia 0 No NICU admit No morbidity • Grade 3 or 4 Intraventricular hemor
Slide 24: Endpoints analyzed across three study populations
Endpoints Were Analyzed Across Three Study Populations/Datasets Datasets All participants accepting and All tested participants with FAS with outcomes added initiating interventions, having Congest 10% of those All tested (with or without FAST added back 4.3% primary outcomes (those back (through im
Slide 25: mITT PRIME trial
mITT PRIME TRIAL 1. Neonatal Morbidity Index (NMI) Excerpt from Abstract, The Pregnancy Journal: • The Odds Ratio (OR) was 0.75 and The Prematurity Risk Assessment Combined significant. Thus, the odds of adverse outcomes on the NMI with Clinical Interventions for Improving scale were 25% lower in th
Slide 26: FAS, ITT
FAS, ITT • The prevention arm demonstrated TABLE 2 favorable outcomes in the full analysis Neonatal outcomes in the intent-to-treat population set and intent-to-treat population of Full Analysis Set of the Intent-to-Treat-Population* 5,018 participants. Substantial Variable Measure Adjusted Rate (95
Slide 27: FAS
FAS • Analysis of the earliest ~10% of births (Quantile) revealed Rates of preterm birth showed a trend toward a substantial extension of reduction, with the stronger effects observed at the gestation (p<0.001) and a 78% increased likelihood of prolonged earliest gestational age gestation (HR = 1.78
Slide 28: Preliminary aggregate PRIME and AVERT meta-analysis: length of stay
Preliminary Aggregate PRIME and AVERT TRIALS mITT Data Meta-Analysis of the Evidence demonstrating the health impacts of the PRIME and AVERT studies PreTRM Test: Neonatal length of hospital stay The two studies evaluating the clinical ® utility of the PreTRM test shared the Co-Primary Outcome: same
Slide 29: Preliminary aggregate PRIME and AVERT meta-analysis: morbidity and mortality
Preliminary Aggregate PRIME and AVERT TRIALS mITT Data Meta-Analysis of the Evidence demonstrating the health impacts of the PRIME and AVERT studies PreTRM Test: Neonatal morbidity and mortality The two studies evaluating the clinical ® Co-Primary Outcome: utility of the PreTRM test shared the Neona
Slide 30: PRIME trial FAS number needed to screen
PRIME TRIAL FAS Number Needed to Screen Number Needed to Screen to prevent NICU admission: widely adopted tests vs PreTRM to prevent NICU admission and NICU days are critical metrics of Transvaginal Ultrasound Cervical Length + Progesterone to prevent test performance for 1 NICU Admission 150 ® comm
Slide 31: Annual economic value of PreTRM from a payer's perspective
Annual economic value of PreTRM from a typical fee-for-service payer’s perspective 5M COVERED LIVES 39,773 pregnancies eligible for Test costs=$29.79M PreTRM and screened 13,920 'higher risk’ + Annual cost savings=$14.8M = 7,656 accept Intervention costs=$9.19M ($2.96 per covered life) interventions
Slide 32: Physician shares a patient pregnancy story
At a 6-week post-partum appointment, I walked into the exam room and my patient greeted me with a big smile and said… “I’m so grateful for the PreTRM Test!” Because after she took it, the results showed an extremely high risk for preterm labor. We worked together during the next 4 months and the out
Slide 33: Commercialization: driving next inflection point
o Publications o Commercialization: Driving Next Inflection Point o Reimbursement Anticipated o Guidelines o Regulatory Milestones o Additional Evidence ©2025 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognost
Slide 34: Our focus: planned approach toward reaching commercial inflection
OUR FOCUS Planned Approach toward Reaching Commercial Inflection Awareness Physician Building & Broad Payer Demand & Early Evidence Guidelines Coverage & Dissemination Payer Coverage Inclusion Reimbursement PRIME and AVERT PRIME and AVERT ACOG Bulletin 234 PRIME and AVERT Publications Publications p
Slide 35: Examples of pivotal RCTs leading to ACOG guidance
There are examples of a pivotal RCT leading to a speedy ACOG practice advisory announcement...and then others that required more time & evidence to change guidelines. HERE ARE (3) CASE STUDIES 1 2 3 Chronic Hypertension ACOG recommended NIPT as an option to ACOG recommended and Pregnancy (CHAP) be “
Slide 36: Sera's strong balance sheet
SERA’S STRONG BALANCE SHEET Sera cash position extends well into 2027 to support reaching seminal revenue inflection point With <$30M annual operating ~$68M spend, strong balance sheet allows Sera to push full steam ahead on Commercialization to Cash, cash equivalents, and reach seminal inflection p
Slide 37: Sera leadership team
Zhenya Lindgardt President & CEO • Former VP of Platform and Customer Engagement, Uber Technologies • Former Senior Partner and Managing Director, The Boston Consulting Group • Former CEO, The Commons Project Foundation • MBA, Harvard University Sera Austin Aerts Chief Financial Officer • Former VP,
Slide 38: Patient testimonial
As a result of the weekly “ check-ins & overall care management, I was well-informed and empowered to advocate for myself and my baby. BONNIE ® Actual PreTRM patient ©2025 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of
Slide 39: Together, we can do better
TOGETHER, WE CAN DO BETTER Educate Providers. Empower MOMS. HELP Babies. Advance Science. Elevate Care. Reach Maternity Deserts. Inform Payers. Evoke Change. ©2025 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Pro